scholarly journals Evaluation of Serum Creatinine Changes With Integrase Inhibitor Use in Human Immunodeficiency Virus-1 Infected Adults

2016 ◽  
Vol 3 (2) ◽  
Author(s):  
Tara A. Lindeman ◽  
Joan M. Duggan ◽  
Eric G. Sahloff
Keyword(s):  
Human Immunodeficiency Virus ◽  
Clinical Trials ◽  
Adverse Events ◽  
Serum Creatinine ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Integrase Inhibitor ◽  
Serious Adverse Events ◽  
Immunodeficiency Virus ◽  
Human Immunodeficiency Virus 1

Abstract This retrospective chart review evaluated changes in serum creatinine and creatinine clearance (CrCl) after initiation of an integrase inhibitor (INSTI)-based regimen as initial treatment in human immunodeficiency virus-infected adults. Serum creatinine and CrCl changes were similar to those seen in clinical trials for INSTIs. No renal-related serious adverse events or discontinuations occurred.

Assessment of Adverse Events Associated With Antiretroviral Regimens for Postexposure Prophylaxis for Occupational and Nonoccupational Exposures to Prevent Transmission of Human Immunodeficiency Virus

2007 ◽  
Vol 28 (6) ◽  
pp. 695-701 ◽  
Author(s):  
A. Luque ◽  
S. Hulse ◽  
D. Wang ◽  
U. Shahzad ◽  
E. Tanzman ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Occupational Exposure ◽  
Adverse Events ◽  
Healthcare Workers ◽  
Health Program ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Preventive Treatment ◽  
Postexposure Prophylaxis ◽  
Immunodeficiency Virus

Objective.To assess adverse events associated with antiretroviral regimens for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP), with a particular focus on the treatment combination of zidovudine, lamivudine, and tenofovir (ZDV-3TC-TDF).Methods.Retrospective chart review for individuals who received HIV PEP for occupational and nonoccupational exposure, and multivariate analyses to identify risk factors for noncompletion of PEP and adverse events associated with PEP.Setting.University of Rochester Health Service Occupational Health Program and University of Rochester AIDS Center.Participants.Healthcare workers who received HIV PEP for occupational exposure from January 1, 1999, to December 31, 2004, and individuals who received HIV PEP for nonoccupational exposure from January 1, 2002, to December 31, 2004.Results.We found increased rates of nausea among subjects who received treatment with ZDV-3TC-TDF and subjects who received treatment with zidovudine, lamivudine, and indinavir (ZDV-3TC-IDV). Analyses showed that female sex was a risk factor for nausea. Compared with subjects who received treatment with ZDV-3TC-TDF, subjects who received treatment with ZDV-3TC-IDV were less likely to not complete the HIV PEP for occupational exposure.Conclusion.Preventive treatment of adverse events may be necessary to ensure completion of HIV PEP.

scholarly journals Impact of Trimethoprim-Sulfamethoxazole Prophylaxis on Etiology and Susceptibilities of Pathogens Causing Human Immunodeficiency Virus-Associated Bacteremia

2002 ◽  
Vol 46 (2) ◽  
pp. 594-597 ◽  
Author(s):  
David A. Wininger ◽  
Robert J. Fass
Keyword(s):  
Staphylococcus Aureus ◽  
Human Immunodeficiency Virus ◽  
Hiv Infection ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Prophylactic Administration ◽  
Antimicrobial Susceptibilities ◽  
Immunodeficiency Virus ◽  
The Impact

ABSTRACT The impact of chronic prophylactic administration of trimethoprim-sulfamethoxazole (SXT) on the ecology and the antimicrobial susceptibilities of bloodstream pathogens in human immunodeficiency virus (HIV)-infected patients was studied using a retrospective chart review. Eighty-nine patients with advanced HIV infection developed 124 episodes of bacteremia with 156 pathogenic isolates. Staphylococcus aureus and Enterobacteriaceae tended to be less common among patients receiving SXT. Isolates from patients receiving SXT were likelier (75%) to be resistant to 20 μg of SXT/ml than those from patients not receiving SXT (33%) (P < 0.001).

Obstacles and options in the quest for drug candidates against vascular disease

2010 ◽  
Vol 104 (07) ◽  
pp. 1-3 ◽  
Author(s):  
Christian Weber
Keyword(s):  
Metabolic Disease ◽  
Human Immunodeficiency Virus ◽  
Clinical Trials ◽  
Chemokine Receptor ◽  
Drug Candidates ◽  
Immunodeficiency Virus ◽  
Aging Populations ◽  
Ccr5 Antagonists ◽  
Cc Chemokine Receptor 5 ◽  
Human Immunodeficiency Virus 1

Summaryhe difficulties in cardiovascular drug development have been exposed by recent clinical trials, which have uncovered various limitations of promising drug candidates. Yet, the imperative to improve medical treatment of atherosclerosis in aging populations afflicted by metabolic disease remains unbroken. Herein alternatives to metabolically active compounds such as glitazones and torcetrapib are introduced and discussed, namely CC chemokine receptor 5 (CCR5) antagonists recently approved for treatment of patients with human immunodeficiency virus-1, interceptors of proatherogenic chemokine interactions, and actively protective pathways. A combination of different strategies may yield improved safety profiles of these therapeutics.

scholarly journals Serious Adverse Events Associated with Off-Label Use of Azithromycin or Fentanyl in Children in Intensive Care Units: A Retrospective Chart Review

2018 ◽  
Vol 21 (1) ◽  
pp. 47-58 ◽  
Author(s):  
Kazeem A. Oshikoya ◽  
Gerold T. Wharton ◽  
Debbie Avant ◽  
Sara L. Van Driest ◽  
Norman E. Fenn ◽  
...  
Keyword(s):  
Intensive Care ◽  
Adverse Events ◽  
Intensive Care Units ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Off Label Use ◽  
Serious Adverse Events ◽  
Off Label ◽  
Label Use

Safety and Immunogenicity of Conventional Subunit and MF59-adjuvanted Influenza Vaccines in Human Immunodeficiency Virus-1-seropositive Patients

2005 ◽  
Vol 33 (4) ◽  
pp. 406-416 ◽  
Author(s):  
G Gabutti ◽  
M Guido ◽  
P Durando ◽  
A De Donno ◽  
M Quattrocchi ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
T Lymphocyte ◽  
Evaluation Agency ◽  
Risk Category ◽  
Serious Adverse Events ◽  
High Risk Category ◽  
Immunodeficiency Virus ◽  
To Receive ◽  
Hiv 1 ◽  
Human Immunodeficiency Virus 1

In this study of influenza vaccination, 37 human immunodeficiency virus (HIV)-1-seropositive patients were randomized to receive either a vaccine with a conventional subunit or one adjuvanted with MF59. Blood samples were collected at the time of vaccination, and then 30 and 180 days later, to evaluate immunogenicity, CD4+ T-lymphocyte count and HIV-1 RNA levels. Seroconversion rates against the three viral strains included in the vaccine ranged between 44% and 72% and 53% and 68% for the adjuvanted vaccine and the subunit vaccine, respectively. Other criteria of the European Medicines Evaluation Agency were also met. Vaccination was not associated with serious adverse events. Local and systemic effects were mild and of short duration. CD4+ T-lymphocyte counts and viraemia levels were not negatively affected by vaccination. These results confirmed the safety and immunogenicity of these currently available vaccines in HIV-1-seropositive patients, thus supporting the recommendation for influenza immunization in this high-risk category.

Sign in / Sign up

Export Citation Format

Share Document